The application of the Keshe Foundation GANS Plasma Technology to prevent and overcome the African Swine Fever and the blue ear disease the large-scale farm trial in China
This article is part of the KF Plasma Times April 2019
Test site:Pig farm with a building holding 829 pigs, aged 50-days-old, with average weight of 25kg.
Test carried out by the request of the Chinese government officials with Keshe Foundation providing the
material and farmers applying the plasma technology.
Collaboration: Keshe Foundation scientist, the management of the farm, their specialists, farm workers
and the renowned Chinese professor supervising the process in live animal husbandry.
The pig farming company owning and operating multiple farms with 2 million pigs in China.
Test date: 19th January 2019 to 3th February 2019
Contents
1. TEST BACKGROUND
The success of the first two trials of treating the African swine fever by Keshe Foundation, has attracted the attention of relevant department in pig farming sector in China.
1.1. FIRST TRIAL
In the first trial carried out by the Keshe Foundation, the GANS plasma technology was applied on a pig which for 3 months was suffering from the ASF. In this case the farmer was supplied with the GANS plasma water and applied it accordingly to the received instructions. Within 3 days, the first signs of recovery were observed and within 7 days, the pig did not show any signs of the fever and entered full recovered (full case documented in Appendix A).
1.2 SECOND TRIAL
The second trial demonstrated the successful reversal and prevention in pigs infected by the ASF, treated within the first two days of detecting the condition. When the symptoms of vomiting and lack of appe- tite were first discovered by the farmer in his small 30 pigs’ farm, the GANS plasma technology was immediately administrated by him. The farm was located in the highly infected ASF area and the farmer is one of the knowledge seekers, following the Keshe Foundation. He contacted the Foundation and requested help, and so the GANS materials were immediately delivered to him. The pig farm and all the pigs were immediately sprayed and watered, by the farmer, with the revolutionary GANS plasma water. The farmer immediately noticed the stoppage of the spreading of the virus to the rest of his pigs and after two weeks of not observing any symptoms of the virus, he manage to sell his pigs on the market (full case documented in Appendix B).
1.3 THIRD TRIAL
Following the success of the first and the second trial, the Keshe Foundation keept the Chinese government officials informed and aware of their achievements and requested for a larger test trial, this time to be observed and controlled by independent observers and officials. In mid-January, the Keshe Foundation was notified by the leading professor appointed by government, to be ready for an 80-pigs test trial. In response, the Foundation prepared materials ready for this trial case.
A meeting with industry experts was arranged by the National Security Department. After explaining in detail, the principle of plasma technology to eliminate viruses and the process of applying the plasma technology, the professor arranged for the Keshe Foundation to visit a farm, belonging to a large pig company in China, which was infected by the ASF virus. The professor and the CEO of the company in writing confirmed to the Keshe Foundation that in one of their farms, a number of pigs were tested positive for the ASF. The professor and the government officials requested the Keshe Foundation to undertake a larger than originally plannedA meeti trial, involving 829 animals. The Keshe Foundation representative, together with the afore-mentioned professor, the CEO, the general manager and the team of technicians and farmers, attended the infected farm on Saturday, 19th January 2019. This farming company, in 2018 bred and sold more than 2 million pigs. The professor informed the Keshe Foundation officials that the company lost thousands of pigs in the past months since the out-break of the virus in China, which has had a serious impact on the company's business.
On attending the farm by the Keshe Foundation and the management of the company, the process of reversal and prevention was immediately implemented. It was then left to the management, the workers and the technicians of the company to observe and document the outcomes of the initiated process. The Keshe Foundation visited the farm the following Saturday and the company was happy with the outcomes.
After 14 days of the start of the trial, the Keshe Foundation and the management of the company met on the 28th January, in the presence of the Chairman, at the headquarter of the company. Based on the success of the initial trials, the company requested from the Keshe Foundation to provide materials, for the prevention of the ASFV and the Blue ear virus, for one of their mother pig farms, where they had positively identified the ASF virus. The GANS water material for this purpose was delivered to the company on February 3rd and was applied on the cohort of 1000 pregnant pigs. At the time of compiling this report (13th February), the Keshe Foundation has not received any reports from the company on any losses or cases of infection on the farm.
2. VIRUSES
2.1 A FRICAN S WINE F EVER VIRUS
African swine fever virus is a large enveloped double stranded DNA virus that is the sole member of the genus Asfivirus within the family Asfarviridae (Asfar = African swine fever and related viruses). African swine fever virus is the only known DNA arbovirus and is transmitted by soft ticks of the genus Ornithodoros. Virus strains are distinguished by their virulence to swine, which ranges from highly lethal to subclinical infection. Virus strains can also be differentiated by their genetic sequences, and various virus-encoded genes, including P72 (also referred to as P73) that can be used for genotyping the virus; however, the genomic diversity of the virus in the nature, remains to be thoroughly characterized. The genome of African swine fever virus contains a unique complement of multigene families.
2.2 P ORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS
Porcine reproductive and respiratory syndrome (PRRS), also called Porcine Blue Ear disease, is a highly contagious disease caused by porcine reproductive and respiratory syndrome (PRRS) virus. Concomitant as lower reproductive, difficult breathing and blue or purple ear, and causing other infectious diseases are its main characteristics. Porcine blue ear disease virus is a single-stranded RNA virus, which lacks a corrective mechanism in the process of viral infection and replication and produces a high mutation rate of offspring virus. The mutation rate of PRRS is 1,000 times higher than that of other DNA viruses, 1 million times faster than the mammalian genome.
3. I NTRODUCTION M.T. K ESHE OF THE NEW SCIENCE AND TECHNOLOGY BY NUCLEAR SCIENTIST
A new discovery and understanding
The new GANS plasma technology of the Keshe Foundation was developed for deep space virus applications and as reported on in this document, successfully resolves the AFS and PRRS virus cases.
In collaboration between the Keshe Foundation’s and the South Sierra Leone University’s scientists, through testing and confirmation of the effectiveness of plasma technology in Ebola virus trials in Africa, it has become clear that the new space plasma technology is very effective when dealing with viruses.
Up to now, the world of science had problems in understanding the operation, working and effects of viruses on human and animal cells. Modern medicine developed antibiotics to deal with the infected cells, but we never fully understood the working of cells which are infected by a virus. Plasma science educates us that we have to look at viruses as energy packages which link and attach themselves to organic cells and until all the energy of this energy pack is used, the signs of the virus will be present in that cell in the human or animal body.
The new space technology by the Keshe Foundation, through the application of plasma energy packs produced by the GANS material, has the ability to deplete the energy of the virus that attached itself to the amino acid or to the cell, by creating a condition that causes the virus to immediately disappear from the affected cell.
